This review article offers an outlook on the use of opioids as therapeutics for treating several
diseases, including cancer and non-cancer pain, and focuses the analysis on the …

This paper is the forty-fourth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

The μ-opioid receptor (μOR), a prototypical G protein-coupled receptor (GPCR), is the target
of opioid analgesics such as morphine and fentanyl. Due to the severe side effects of current …

Novel synthetic opioids (NSOs), including both fentanyl and non-fentanyl analogs that act as
μ-opioid receptor (MOR) agonists, are associated with serious intoxication and fatal …

Opioid use disorder and opioid overdose continue to be significant public health challenges
despite the availability of effective treatments. Methocinnamox (MCAM) is a novel, long …

Methocinnamox (MCAM), a long-acting μ-opioid receptor antagonist, attenuates the positive
reinforcing effects of opioids, such as heroin and fentanyl, suggesting it could be an effective …

Without substantial intervention, the opioid crisis is projected to continue, underscoring the
need to develop new treatments for opioid use disorder (OUD). One drug under …

The opioid epidemic is an ongoing public health crisis, and the United States health system
is overwhelmed with increasing numbers of opioid-related overdoses. Methocinnamox …

Opioid overdose and opioid use disorder continue to be significant public health challenges
despite the availability of effective medications and significant efforts at all levels of society …

Novel synthetic opioids (NSOs), including both fentanyl and non-fentanyl analogs that act as
the μ-opioid receptor (MOR) agonists, are associated with serious intoxication and fatal …